RELMADA THERAPEUTICS, INC. (RLMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 3.5K 7K 10.5K Q1 '13: 10.1K Q2 '13: 6.4K Q3 '13: 6.6K Q4 '13: 5.1K Q1 '14: 4.8K Q2 '14: 3.2K Q1 '13 Q2 '13 Q3 '13 Q4 '13 Q1 '14 Q2 '14

Gross Profit TTM

0 900 1.8K 2.7K Q1 '13: 2.4K Q2 '13: 1.4K Q3 '13: 1.6K Q4 '13: 1.1K Q1 '14: 958 Q2 '14: 473 Q1 '13 Q2 '13 Q3 '13 Q4 '13 Q1 '14 Q2 '14

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q1 '22: -112.4M Q2 '22: -125.7M Q3 '22: -141.6M Q4 '22: -160.6M Q1 '23: -156.7M Q2 '23: -161.2M Q3 '23: -151.1M Q4 '23: -131.6M Q1 '24: -115.6M Q2 '24: -103.7M Q3 '24: -98.5M Q4 '24: -91.3M Q1 '25: -91.6M Q2 '25: -83.9M Q3 '25: -79.1M Q4 '25: -70.5M Q1 '26: -57.8M Q2 '26: -59.1M Q3 '26: -60.3M Q4 '26: -65.1M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q1 '22: -112.1M Q2 '22: -125.8M Q3 '22: -143.3M Q4 '22: -156.7M Q1 '23: -153.5M Q2 '23: -157M Q3 '23: -143.6M Q4 '23: -129M Q1 '24: -111.6M Q2 '24: -98.8M Q3 '24: -94.3M Q4 '24: -86.8M Q1 '25: -86.5M Q2 '25: -80M Q3 '25: -75.7M Q4 '25: -67.8M Q1 '26: -56.2M Q2 '26: -57.4M Q3 '26: -58.9M Q4 '26: -61.9M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

Cost of Revenue TTM

0 3K 6K 9K Q1 '13: 7.6K Q2 '13: 5K Q3 '13: 5K Q4 '13: 4K Q1 '14: 3.9K Q2 '14: 2.7K Q1 '13 Q2 '13 Q3 '13 Q4 '13 Q1 '14 Q2 '14

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q1 '22: -61.1M Q2 '22: -91.9M Q3 '22: -95.2M Q4 '22: -99.6M Q1 '23: -105.6M Q2 '23: -103.8M Q3 '23: -100.9M Q4 '23: -92.5M Q1 '24: -77.3M Q2 '24: -51.7M Q3 '24: -48.2M Q4 '24: -48.2M Q1 '25: -53.2M Q2 '25: -51.8M Q3 '25: -56.8M Q4 '25: -49.9M Q1 '26: -40M Q2 '26: -45.8M Q3 '26: -42.8M Q4 '26: -46M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

Free Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q2 '15: -9.5M Q3 '15: -12.9M Q4 '15: -16.3M Q1 '16: -17.1M Q2 '16: -16.1M Q3 '16: -15.4M Q4 '16: -13.7M Q1 '17: -12.7M Q2 '17: -10.2M Q3 '17: -8.3M Q4 '17: -6.5M Q1 '18: -5.3M Q2 '18: -5M Q3 '18: -4.8M Q4 '18: -6M Q2 '15 Q4 '15 Q2 '16 Q4 '16 Q2 '17 Q4 '17 Q2 '18 Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q1 '17: 12M Q2 '17: 12M Q3 '17: 12M Q3 '21: 16.6M Q4 '21: 17.1M Q1 '22: 17.5M Q3 '22: 28.4M Q4 '22: 29.9M Q1 '23: 30.1M Q3 '23: 30.1M Q4 '23: 30.1M Q1 '24: 30.1M Q3 '24: 30.1M Q4 '24: 30.2M Q1 '25: 30.2M Q3 '25: 30.4M Q4 '25: 33.2M Q1 '26: 33.2M Q3 '26: 86.6M Q4 '26: 112.4M Q2 '17 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25 Q4 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q1 '22: -6.63 Q2 '22: -7.14 Q3 '22: -7.20 Q4 '22: -6.97 Q1 '23: -5.84 Q2 '23: -5.30 Q3 '23: -4.77 Q4 '23: -4.28 Q1 '24: -3.70 Q2 '24: -3.27 Q3 '24: -3.12 Q4 '24: -2.87 Q1 '25: -2.86 Q2 '25: -2.65 Q3 '25: -2.51 Q4 '25: -2.22 Q1 '26: -1.80 Q2 '26: -1.47 Q3 '26: -1.11 Q4 '26: -0.92 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.